Paul Maciocia

thelancet.com/journals/lanha… Happy to share 15 year follow-up of our study of early rituximab vs watchful waiting for advanced stage, asymptomatic, low tumour burden FL. Substantial delay in TTNT highlights the value of early R for pts seeking to defer/avoid chemo. #lymsm #lymphoma

Focused on improving relapsed/refractory T-ALL patient outcomes, Maciocia et al. identified CD21 as a promising target for CAR T cell therapy. bit.ly/4iG2uie  @MaciociaNicola @CR_UK  @paulmaciocia

Up next we have @MaciociaNicola @UCLTRO on anti-CD21 #CART cells for T-ALL #YoungEHA #BSH25 - room M4!

My PhD paper finally out today! Tweetorial coming but here is the link for now. Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia | Sci Trans Med science.org/doi/10.1126/sc… @paulmaciocia @uclcancer @CR_UK @science

Nicola PhD paper finally out today after years and years of work. Hugely proud and it’s a cool story too. She will do a tweetorial soon! @nicolamaciocia @ucl @uclcancer @CRUKCOLcentre @ScienceMagazine @UKRI_News science.org/doi/10.1126/sc…

To mark #WorldCancerDay, our friends at @UCLmedsci are hosting a virtual event on Transforming Cancer Care (6 February) featuring @UCLAlumni @DoctorChrisVT, @paulmaciocia, and other @UCL experts at the frontiers of cancer research. Register: bit.ly/3COG7bw

CAR-T cell therapies for T cell malignancies: does cellular immunotherapy represent the best chance of cure? ashpublications.org/bloodadvances/…

Tonight at 6:30pm on Radio 4 - ep 4️⃣ of Best Medicine! Catch @drclaireroddie from our City of London Centre, talking about CAR T-Cells and their importance when it comes to treating cancer 🧫 Catch-up later 👉 bbc.co.uk/programmes/m00…

Well deserved, my friend!🤩